Pivotal bioVenture Partners Investment Advisor’s Rallybio RLYB Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio RLYB Stock Details RLYB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.81M	Hold	300,579	–	–	1.56%	12
2026 Q1	$2.7M	Sell	300,579 -2	-0%	-$14	0.96%	11
2025 Q4	$1.65M	Hold	300,581	–	–	0.64%	11
2025 Q3	$1.2M	Hold	300,581	–	–	0.69%	9
2025 Q2	$813K	Hold	300,581	–	–	0.5%	11
2025 Q1	$1.56M	Hold	300,581	–	–	1.27%	8
2024 Q4	$2.31M	Hold	300,581	–	–	1.56%	8
2024 Q3	$2.81M	Hold	300,581	–	–	1.67%	8
2024 Q2	$3.22M	Hold	300,581	–	–	2.48%	6
2024 Q1	$4.45M	Hold	300,581	–	–	2.86%	6
2023 Q4	$5.75M	Hold	300,581	–	–	1.46%	8
2023 Q3	$8.1M	Hold	300,581	–	–	3.23%	5
2023 Q2	$13.6M	Hold	300,581	–	–	4.49%	5
2023 Q1	$13.7M	Hold	300,581	–	–	5.65%	5
2022 Q4	$15.8M	Buy	300,581 +16,667	+6%	+$984K	6.87%	3
2022 Q3	$32.9M	Hold	283,914	–	–	12.01%	2
2022 Q2	$17.1M	Hold	283,914	–	–	8.64%	3
2022 Q1	$15.9M	Hold	283,914	–	–	7.5%	3
2021 Q4	$21.7M	Hold	283,914	–	–	9.06%	3
2021 Q3	$39.9M	Buy	+283,914	New	+$33.3M	14.11%	2

Other funds holding RLYB

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's RLYB Position: Q2 2026 in Review

Pivotal bioVenture Partners Investment Advisor held its Rallybio (RLYB) position steady in Q2 2026 at 300,579 shares worth $4.81M. The position accounts for 1.56% of the portfolio, ranked #12.

Pivotal bioVenture Partners Investment Advisor first reported a position in RLYB in Q3 2021 and has held it in 20 quarters since. The position peaked at $39.9M in Q3 2021. 37 funds tracked by Wall St. Rank hold RLYB as of Q2 2026.

Pivotal bioVenture Partners Investment Advisor held 300,579 shares of Rallybio worth $4.81M as of Q2 2026.
Pivotal bioVenture Partners Investment Advisor left its Rallybio share count unchanged in Q2 2026.
Rallybio made up 1.56% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q2 2026, its #12 holding.
Pivotal bioVenture Partners Investment Advisor first reported a position in Rallybio in Q3 2021 and has held it in 20 quarters since.
Pivotal bioVenture Partners Investment Advisor's Rallybio position peaked at $39.9M in Q3 2021.
37 funds tracked by Wall St. Rank held Rallybio as of Q2 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2026, filed 13 Aug 2026.